Baseline demographic and clinical characteristics of study subjects
| Yoga | Control | |||
|---|---|---|---|---|
| Randomised | Complete* | Randomised | Complete* | |
| FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; AQLQ = asthma related quality of life questionnaire; CAS = combined asthma score; PD20FEV1 = dose of methacholine provoking a fall in FEV1 of 20% or more. *Subjects who had outcome assessments performed at the end of the treatment period. †Daily dose of inhaled steroids in beclomethasone μg equivalents. These were calculated on the assumption that beclomethasone 2000 μg = budesonide 1600 μg = fluticasone 1000 μg. ‡Median values. | ||||
| Number | 30 | 21 | 29 | 26 |
| Mean age (years) | 36 | 37 | 36 | 37 |
| Female (n) | 14 | 11 | 17 | 15 |
| Ex-smokers (n) | 10 | 7 | 11 | 10 |
| Duration of asthma (years) | 25 | 25 | 22 | 22 |
| Mean inhaled steroid dose (μg)† | 2458 | 2274 | 1927 | 1918 |
| Mean FEV1 (% predicted) | 75% | 76% | 76% | 73% |
| Mean FEV1/FVC ratio | 0.70 | 0.71 | 0.75 | 0.74 |
| Mean AQLQ Total score | 1.7 | 1.5 | 1.5 | 1.5 |
| Mean AQLQ Breathlessness score | 1.5 | 1.4 | 1.5 | 1.5 |
| Mean AQLQ Mood score | 1.7 | 1.8 | 1.3 | 1.3 |
| Mean AQLQ Social score | 1.4 | 1.2 | 1.4 | 1.5 |
| Mean AQLQ Concerns score | 1.9 | 1.7 | 1.6 | 1.7 |
| Mean morning peak flow | 369 | 372 | 365 | 363 |
| Peak flow (low % high) | 76% | 77% | 72% | 70% |
| CAS‡ (max 12) | 10 | 10 | 10 | 10 |
| PD20FEV1 (μmol) | 1.20 (n = 22) | 1.51 (n = 16) | 1.21 (n = 22) | 1.29 (n = 19) |